Magd Zakaria

944 total citations
27 papers, 305 citations indexed

About

Magd Zakaria is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Magd Zakaria has authored 27 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 10 papers in Neurology and 6 papers in Rheumatology. Recurrent topics in Magd Zakaria's work include Multiple Sclerosis Research Studies (21 papers), Peripheral Neuropathies and Disorders (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Magd Zakaria is often cited by papers focused on Multiple Sclerosis Research Studies (21 papers), Peripheral Neuropathies and Disorders (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Magd Zakaria collaborates with scholars based in Egypt, Saudi Arabia and Kuwait. Magd Zakaria's co-authors include Saeed Bohlega, Jihad Inshasi, Maurice Dahdaleh, Raed Alroughani, Bassem Yamout, Mohammad Ali Sahraian, Mohammed Aljumah, Taoufik Alsaadi, Samia J. Khoury and Salam Koussa and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and European Journal of Neurology.

In The Last Decade

Magd Zakaria

25 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Magd Zakaria Egypt 10 232 88 61 49 40 27 305
Maurice Dahdaleh Saudi Arabia 11 230 1.0× 70 0.8× 55 0.9× 54 1.1× 48 1.2× 16 285
Licínio Craveiro Switzerland 8 187 0.8× 98 1.1× 61 1.0× 27 0.6× 72 1.8× 27 258
H-P Hartung Germany 9 190 0.8× 92 1.0× 60 1.0× 72 1.5× 100 2.5× 10 330
Lana Zhovtis Ryerson United States 12 374 1.6× 188 2.1× 181 3.0× 51 1.0× 86 2.1× 36 509
Claire Hara-Cleaver United States 8 376 1.6× 99 1.1× 101 1.7× 83 1.7× 31 0.8× 11 436
Christos Smias Greece 10 122 0.5× 27 0.3× 83 1.4× 21 0.4× 71 1.8× 14 313
Nordau Kanigsberg Canada 11 79 0.3× 32 0.4× 45 0.7× 76 1.6× 24 0.6× 28 326
Bibiana Quirant‐Sánchez Spain 14 104 0.4× 30 0.3× 53 0.9× 24 0.5× 171 4.3× 36 392
Stephen Kamin United States 4 128 0.6× 88 1.0× 35 0.6× 51 1.0× 21 0.5× 5 190
Rajesh Shetty India 11 131 0.6× 49 0.6× 20 0.3× 38 0.8× 47 1.2× 24 336

Countries citing papers authored by Magd Zakaria

Since Specialization
Citations

This map shows the geographic impact of Magd Zakaria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magd Zakaria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magd Zakaria more than expected).

Fields of papers citing papers by Magd Zakaria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magd Zakaria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magd Zakaria. The network helps show where Magd Zakaria may publish in the future.

Co-authorship network of co-authors of Magd Zakaria

This figure shows the co-authorship network connecting the top 25 collaborators of Magd Zakaria. A scholar is included among the top collaborators of Magd Zakaria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magd Zakaria. Magd Zakaria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zakaria, Magd, Nevin Shalaby, Alaa Elmazny, et al.. (2025). Development and validation of a scoring system for predicting disease activity in treatment-naïve patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 94. 106278–106278. 1 indexed citations
2.
Berger, Thomas, Markus Zeitlinger, Veronica Popescu, et al.. (2025). Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists. European Journal of Neurology. 32(4). e70140–e70140.
3.
Vermersch, Patrick, Laura Airas, Thomas Berger, et al.. (2025). The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors. Frontiers in Immunology. 16. 1495529–1495529. 3 indexed citations
4.
Alroughani, Raed, Magd Zakaria, Edward Cupler, & Karim Taha. (2023). Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study. Frontiers in Neurology. 14. 1257455–1257455.
5.
Zakaria, Magd, et al.. (2023). Assessment of the role of telemedicine in the outcome of multiple sclerosis patients. The Egyptian Journal of Neurology Psychiatry and Neurosurgery. 59(1). 2 indexed citations
6.
Pugliatti, Maura, Hans‐Peter Hartung, Celia Oreja‐Guevara, et al.. (2022). Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. Frontiers in Immunology. 13. 1045101–1045101. 7 indexed citations
7.
Alroughani, Raed, Ahmed Ali Hassan, Naji Riachi, et al.. (2021). Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA). Clinical Neurology and Neurosurgery. 203. 106576–106576. 3 indexed citations
8.
Shokri, Hossam, et al.. (2021). The Clinical Characteristics of Patients with Pre-Existing Leukoaraiosis Compared to Those Without Leukoaraiosis in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases. 30(9). 105956–105956. 6 indexed citations
9.
Yamout, Bassem, Magd Zakaria, Jihad Inshasi, et al.. (2021). MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders. 56. 103225–103225. 23 indexed citations
10.
Hamid, Eman, et al.. (2021). Telephone-based assessment of multiple sclerosis patients at Ain Shams University Hospital in the coronavirus disease 2019 pandemic. The Egyptian Journal of Neurology Psychiatry and Neurosurgery. 57(1). 66–66. 2 indexed citations
11.
Bohlega, Saeed, Cavit Boz, Jihad Inshasi, et al.. (2020). Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review. Neurology and Therapy. 9(1). 55–66. 25 indexed citations
12.
Yamout, Bassem, Mohammad Ali Sahraian, Saeed Bohlega, et al.. (2019). Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders. 37. 101459–101459. 75 indexed citations
13.
Nahas, Nevine El, et al.. (2019). Clinical Characteristics of Borderzone Infarction in Egyptian Population. Journal of Stroke and Cerebrovascular Diseases. 28(5). 1178–1184. 2 indexed citations
14.
Aref, Hany, et al.. (2019). Magnetic resonance imaging markers of disability in Egyptian multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 36. 101417–101417. 3 indexed citations
15.
Aref, Hany, et al.. (2018). Vitamin D and body mass index in Egyptian multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 28. 313–316. 11 indexed citations
16.
Dahdaleh, Maurice, Raed Alroughani, Mohammed Aljumah, et al.. (2016). Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?. International Journal of Neuroscience. 127(10). 944–951. 4 indexed citations
17.
Zakaria, Magd, et al.. (2016). Clinical characteristics of patients with multiple sclerosis enrolled in a new registry in Egypt. Multiple Sclerosis and Related Disorders. 10. 30–35. 15 indexed citations
18.
Alroughani, Raed, Ayşe Altıntaş, Mohammed Al Jumah, et al.. (2016). Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. SHILAP Revista de lepidopterología. 2016. 1–8. 35 indexed citations
19.
Zakaria, Magd. (2015). Smoke and mirrors: Limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis. Multiple Sclerosis and Related Disorders. 4(3). 187–191. 8 indexed citations
20.
Bohlega, Saeed, Maurice Dahdaleh, Abdulkader Daif, et al.. (2013). Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region. International Journal of Neuroscience. 124(9). 635–641. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maurice Dahdaleh Breakdown of academic impact, for papers by Licínio Craveiro Breakdown of academic impact, for papers by H-P Hartung Breakdown of academic impact, for papers by Lana Zhovtis Ryerson Breakdown of academic impact, for papers by Claire Hara-Cleaver Breakdown of academic impact, for papers by Christos Smias Breakdown of academic impact, for papers by Nordau Kanigsberg Breakdown of academic impact, for papers by Bibiana Quirant‐Sánchez Breakdown of academic impact, for papers by Stephen Kamin Breakdown of academic impact, for papers by Rajesh Shetty
Rankless by CCL
2026